Exact Sciences diskutieren
Exact Sciences
WKN: 590273 / Symbol: EXAS / Name: EXACT Sci / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
86,17 €
-0,52 %
Exact Sciences Co. (NASDAQ: EXAS) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $75.00 to $70.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $60.00 price target on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Barclays PLC from $65.00 to $55.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $60.00 price target on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Robert W. Baird from $69.00 to $72.00. They now have an "outperform" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Evercore ISI from $60.00 to $66.00. They now have an "outperform" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Barclays PLC from $55.00 to $75.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Corporation (NASDAQ: EXAS) had its price target lowered by analysts at Barclays PLC from $75.00 to $65.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Corporation (NASDAQ: EXAS) had its price target raised by analysts at Evercore ISI from $66.00 to $68.00. They now have an "outperform" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Corporation (NASDAQ: EXAS) had its price target lowered by analysts at Barclays PLC from $65.00 to $55.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Corporation (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Cowen Inc.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Corporation (NASDAQ: EXAS) had its price target lowered by analysts at Evercore ISI from $68.00 to $64.00. They now have an "outperform" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Corporation (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $70.00 to $60.00. They now have an "overweight" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences Corporation (NASDAQ: EXAS) had its price target lowered by analysts at BTIG Research from $65.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at Craig Hallum from $65.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences (NASDAQ:EXAS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Ratings data for EXAS provided by MarketBeat
Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at BTIG Research from $60.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Exact Sciences (NASDAQ:EXAS) had its price target raised by analysts at Stifel Nicolaus from $67.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for EXAS provided by MarketBeat
Neueste Beiträge
BTIG_Research in Workday, Inc. diskutieren